Amgen beefs up its late-stage pipeline with a $400M cash deal to go up against heavyweight rivals in a PhIII atopic dermatitis showdown
Three months after Kyowa Kirin claimed a hit for their mid-stage program testing the anti-OX40 antibody KHK4083 for moderate to severe atopic dermatitis, Amgen is going all-in on the drug, paying $400 million in cash to line up ex-Japan rights in what’s shaping up as another big, late-stage rivalry in the megablockbuster field.
We didn’t get to see data from Kyowa Kirin’s statement on the Phase II success back in February, but based on the Amgen upfront and the commitment to shared research costs and co-promotion in the US while backing it all up with $850 million in milestones — plus royalties — the results have to register a significant response in order to justify jumping into this packed field of contestants.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 109,900+ biopharma pros reading Endpoints daily — and it's free.